Aug 2026· Cancer Treatment and Research Communications· Vol 49, pp.
101411
· 0 citations· 22 references
Medicine
TL;DR
The hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC is suggested, although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival.
Abstract
Purpose
Even though thyroid transcription factor-1 (TTF-1)-negative non-squamous non-small cell lung cancer (NSCLC) is associated with a poor prognosis, the optimal treatment regimens have not been established. We conducted this multicenter retrospective study to evaluate the association between specific treatment choices and survival outcomes in this population.
Methods
We retrospectively analyzed data from patients with TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitors plus chemotherapy between 2019 and 2022. TTF-1 expression levels were assessed by immunohistochemistry performed in routine clinical practice at each participating institution. Patients with EGFR or ALK driver alterations were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated to compare treatment options, focusing particularly on the use of CTLA-4 antibodies.
Results
A total of 58 patients were included in the analysis. Univariate analysis revealed no association between PFS and treatment options, including CTLA-4 antibodies, pemetrexed, and vascular endothelial growth factor (VEGF) inhibitors. Conversely, OS was longer in patients treated with CTLA-4 antibody regimens (p = 0.045, log-rank test). Multivariate analysis showed a hazard ratio of 0.36 (95% confidence interval: 0.12-1.07) for OS in patients receiving CTLA-4 antibody regimens compared with those who did not.
Conclusion
Although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival, it did suggest the hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC.
Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.
Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al.· Frontiers in Oncology· 0 citations
BACKGROUND
For advanced lung cancer patients, an increasing number of long responders to Immune Checkpoint Inhibitors (ICI) is observed. Thus, the optimal treatment duration remains unclear whereas indefinite treatment is associated to immune-related adverse events (irAEs) and financial burden.
OBJECTIVE
To describe...
Arnaud De Gunten, A. Mogenet, A. Bronstein et al.· Lung Cancer· 0 citations
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1, programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4, have become a standard treatment resulting in improved outcomes in advanced non-small cell lung cancer (NSCLC); however, the influence of seasonal variations on trea...
Zhang-Xuan Chen, Jing-Si Chen, Yang Yao et al.· Oncology Letters· 0 citations
Higher IChIS was independently associated with shorter PFS in patients with advanced NSCLC receiving ICIs, supporting its potential role as a simple and readily available prognostic biomarker.
Ismail Dilli, E. E. Kavak, M. Atak et al.· Journal of Clinical Medicine· 0 citations
Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...
A. Agbarya, N. S. Shrem, Asmah Miari et al.· Frontiers in Immunology· 0 citations
Multivariate analysis revealed that SDC4 subtype, bone metastasis status, and the use of TKIs as first-line treatment were independent prognostic factors for PFS of first-line therapy.